Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Silo Pharma, Inc. (Nasdaq: SILO) SEC filings page on Stock Titan provides direct access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into Silo’s status as a developmental-stage biopharmaceutical and cryptocurrency treasury company, its capital structure, and its governance and compliance framework.
For investors analyzing Silo’s biopharmaceutical programs and digital assets strategy, key filings include current reports on Form 8-K, the Definitive Proxy Statement (DEF 14A), and registration statements such as Form S-1. Recent 8-Ks describe material events including the launch of a cryptocurrency advisory board, asset purchases related to crypto software and domains, Nasdaq minimum bid price notifications, strategic agreements with Fireblocks for digital asset custody, and securities purchase agreements for registered direct offerings and concurrent private placements.
The Form S-1 registration statement filed in October 2025 details the resale of shares issuable upon exercise of investor and placement agent warrants issued in a financing transaction, including warrant terms, exercise prices, and potential proceeds if exercised. This document helps readers understand how warrant exercises could affect Silo’s share count and capital resources.
Silo’s DEF 14A proxy statement outlines matters submitted to shareholders at the 2025 annual meeting, such as director elections, ratification of the independent registered public accounting firm, authorization of a reverse stock split within a specified range, and an amendment to increase shares reserved under the equity incentive plan. An 8-K reporting the voting results shows how shareholders acted on these proposals.
Additional 8-K filings cover topics such as an evaluation license and option agreement with the University of Maryland, Baltimore for intellectual property related to central nervous system-homing peptides and the establishment of a cryptocurrency advisory board with related equity compensation. Together, these documents provide a regulatory record of Silo’s efforts to advance its SPC-15 and SP-26 programs, manage listing compliance on the Nasdaq Capital Market, and implement its crypto treasury strategy.
On Stock Titan, these filings are updated as they appear on EDGAR, and AI-powered tools can be used to quickly surface items related to financings, listing compliance, governance changes, and strategic agreements within Silo Pharma’s disclosure history.